28
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      A history of herd immunity

      news
      a , b
      Lancet (London, England)
      Elsevier Ltd.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          As many countries around the world recognised the magnitude of the COVID-19 pandemic in March, 2020, some seemed to put their faith in herd immunity. UK pandemic adviser Graham Medley, for example, said that “We are going to have to generate what we call herd immunity”, which would require “a nice big epidemic”. When the idea received furious criticism, British officials denied that herd immunity had ever been part of their plan. A run at herd immunity in Sweden prompted mathematician Marcus Carlsson to object: “we are being herded like a flock of sheep toward disaster”. In August, WHO's Michael Ryan warned journalists “we are nowhere close to the levels of immunity required to stop this disease transmitting. We need to focus on what we can actually do now to suppress transmission and not live in hope of herd immunity being our salvation.” That did not end the debate. In late August sources revealed that the White House might be pondering a policy of herd immunity. Officials issued a prompt denial. The appeal of herd immunity is easy to understand: if it is reached, an epidemic ends. But the illness and death such an approach would require have prompted a strong backlash. The language of herd immunity is part of the problem. A herd usually describes domesticated animals, especially livestock. Herd animals like cows, goats, or sheep are sacrificed for human consumption. Few humans want to be part of that kind of herd. How did herd immunity enter the language of public health? The phrase seems to have first appeared in the work of American livestock veterinarians concerned about “contagious abortion”—epidemics of spontaneous miscarriage—in cattle and sheep. By the 1910s, it had become the leading contagious threat to cattle in the USA. Farmers destroyed or sold affected cows. Kansas veterinarian George Potter realised that this was the wrong approach. Writing with Adolph Eichhorn in 1916 in the Journal of the American Veterinary Medical Association, he envisioned “herd immunity”. As he wrote in 1918, “Abortion disease may be likened to a fire, which, if new fuel is not constantly added, soon dies down. Herd immunity is developed, therefore, by retaining the immune cows, raising the calves, and avoiding the introduction of foreign cattle.” “Frontispiece, no. 1. The human herd: Greenwich Hospital Schoolboys at dinner” in Active Immunization Against Diphtheria: its Effect on the Distribution of Antitoxic Immunity and Case and Carrier Infection (1934) by Sheldon F Dudley, Percival M May, and Joseph A O'Flynn © 2020 Medical Research Council/Special Report Series, No 195/London: HM Stationery Office/1934 2020 Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. Potter's concept reached the UK in 1917 and 1920 in summaries in Veterinary Review and Scottish Agriculture. It arrived at a crucial moment. Armies and navies struggled against infections throughout World War 1. Medical professionals worked to identify and treat pathogens, and also to understand their population ecology. How did pathogen virulence and population resistance drive the rise and fall of epidemic waves? In The Lancet in July, 1919, bacteriologist W W C Topley described experimental epidemics he created in groups of mice. Unless there was a steady influx of susceptible mice, the rising prevalence of immune individuals would end an epidemic. In a 1923 article in the Journal of Hygiene, he and G S Wilson described this phenomenon as “herd immunity”. The idea moved into medicine. In 1922, Topley suggested a parallel between outbreaks in mice and children: “Such a likeness would seem to exist in the case of epidemic diseases affecting children of school age.” He also wondered whether measures already “in vogue in dealing with epidemics among live-stock, where methods of segregation are so much more easily enforced than among human populations”, might inform decisions about school closings amid epidemics. Topley's musings soon found their test. In 1923 Sheldon Dudley, professor of pathology at the Royal Naval Medical School, became aware of epidemics of diphtheria at the Royal Hospital School in Greenwich. The school provided laboratory-like conditions, with a homogeneous group of male students, in good physical shape, who entered in batches several times a year, where they slept in dormitories of 70 to 126 beds. Dudley studied these students and complemented his data with studies from the Grand Fleet during the war and from the training ship HMS Impregnable (grievously susceptible, it turned out, to epidemics). Dudley published reports for the Medical Research Council on diphtheria and scarlet fever, droplet infections, and diphtheria immunisations. He believed that Topley's analysis of “experimental epidemics among communities of mice provides at more than one point striking parallels to the observed phenomena among the boys at Greenwich”. In a 1924 article in The Lancet, Dudley applied “herd immunity” to humans. In a 1929 article, “Human Adaptation to the Parasitic Environment”, he wrote, “I will now consider the community, or the herd…Nations may be divided into urban or rural herds. Or we can contrast the shoregoing herd with the sailor herd, or herds dwelling in hospitals can be compared with those who live in mental hospitals.” Dudley's glide from animal to human drew on established British traditions of animal symbolism. As historian Harriet Ritvo argues in The Animal Estate, animals have long served in England as figures for representing national types, lineages, and identities. When Dudley, as surgeon, researcher, and medical administrator, wrote of the “English herd”, he tacitly invoked his own role in a project of national stewardship. Dudley's language, however, did give some readers pause. He prefaced his 1934 report, Active Immunization Against Diphtheria, with photographs of “The human herd” (Greenwich boys at dinner) and “The bacterial herd” (colonies of diphtheria on culture media). As a commentator in The Lancet noted, “Anyone with a modern sense of social progress might well wonder whether the phrase ‘the human herd’ is here used in a scientific or in ironical sense, but perhaps in this case the meanings are not far apart.” Such musings notwithstanding, “herd immunity” became a fixture of epidemiology by the 1930s. Discussions of herd immunity for influenza, polio, smallpox, and typhoid appeared in textbooks, journals, and public health reports in England, Australia, and the USA. The idea also intersected with eugenic notions of racial difference at a time when eugenic racism was ascendant in the UK and the USA. An author of a 1931 Lancet piece wondered whether specific groups, for instance the Maori, had “racial herd-immunity”. The early researchers never settled on a clear definition. Dudley preferred a focus on what share of a herd had acquired resistance from natural exposure or immunisation. Topley elaborated a more expansive concept. As he explained in the Journal of the Royal Army Medical Corps in 1935, herd immunity encompassed not just the distribution of immunity, but also the social factors determining the herd's exposure. The “English herd”—those living in England—had herd immunity to plague, malaria, and typhus because they no longer lived in close association with the requisite vectors. Herd immunity took on fresh prominence in the 1950s and 1960s as new vaccines raised crucial questions for public health policy. What share of a population had to be vaccinated to control or eradicate a disease? The idea surged again after 1990 as public health officials worked to achieve sufficient levels of vaccine coverage. But the language of “herd immunity” continued to resonate with visions of people being treated as animals to be domesticated and culled—anxieties reflected in dystopian fiction about farmed humans, from H G Wells' Time Machine to David Mitchell's Cloud Atlas. The association between livestock and sacrifice could have contributed to the objections in March to policies that would have asked many people to be sickened or killed by SARS-CoV-2 in pursuit of herd immunity. The phrase, however, has not disappeared. Publics face the same problem with COVID-19 in 2020 that Dudley faced with diphtheria in the 1920s: whether a contagious droplet infection can be controlled, without a vaccine or therapeutic, through social distancing and hygiene alone. Studies in June and July cast doubt on prospects for herd immunity: despite months of exposure, antibody surveys found a low seroprevalence, less than 10%, in cities in Spain and Switzerland. Commentators in The Lancet concluded that “In light of these findings, any proposed approach to achieve herd immunity through natural infection is not only highly unethical, but also unachievable”. Sceptics raised other concerns, observing that other coronaviruses induce only transient antibody defences. Defenders of herd immunity, however, have persisted. Some argue that antibodies are not essential because SARS-CoV-2 might induce durable T-cell immunity. Others speculate that if the most susceptible members of a community are infected first, then herd immunity might be achieved after exposure of just 20% of the population. With potential vaccines still likely to be many months away, and with lockdowns and social distancing causing social and economic disruption, there are no ideal options. British public health expert Raj Bhopal likened the situation to being in zugzwang, “a position in chess where every move is disadvantageous where we must examine every plan, however unpalatable”. He sought to overcome the animal connotations of “herd immunity” by encouraging the use of “population immunity” instead. Changing the label of herd immunity might remove the connotations but not fix the problem. Without a vaccine, many people would have to die from COVID-19 before population immunity is achieved. COVID-19 mortality in the UK and the USA has already taken a disproportionate toll on poor and minority groups, a reflection of systemic racism and poverty. At one urgent care centre in a largely Latino, working-class neighbourhood in New York City—named, remarkably, Corona—68·4% of antibody tests came back positive. But it remains unclear whether these antibodies will protect individuals or generate herd immunity. Until there exist vaccines that can do both of those things, societies will need to continue to try to control the spread of the virus at the local level through public health measures and community action, to protect the most vulnerable people, and to support public health and medical systems. We should not simply put our faith in the immunity of our herd.

          Related collections

          Most cited references10

          • Record: found
          • Abstract: found
          • Article: not found

          SARS-CoV-2 seroprevalence in COVID-19 hotspots

          Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has surprised the world with its range of disease manifestations, from asymptomatic infection to critical illness leading to hospital admission and death.1, 2 Due to the high proportion of asymptomatic or mild infections (approximately 80%), data restricted to laboratory-confirmed cases do not capture the true extent of the spread or burden of the virus, or its infection-fatality ratio. 2 Therefore, serological detection of specific antibodies against SARS-CoV-2 can better estimate the true number of infections. Due to co-circulation of other human coronaviruses, serology for SARS-CoV-2 is not trivial. Antibody cross-reactivity with other human coronaviruses has been largely overcome by using selected viral antigens, and several commercial assays are now available for SARS-CoV-2 serology. However, despite high sensitivity and specificity, a setting with a low pretest probability, such as current population-based seroprevalence studies, warrants careful validation of results. 3 Extensive previous assay validation in well characterised serum samples and confirmation of positive results are thus necessary to prevent false-positive findings from confounding seroprevalence rates. The first SARS-CoV-2 seroprevalence studies from cohorts representing the general population have become available from COVID-19 hotspots such as China, the USA, Switzerland, and Spain.4, 5, 6, 7, 8 In The Lancet, Marina Pollán and colleagues 6 and Silvia Stringhini and colleagues 7 separately report representative population-based seroprevalence data from Spain and Switzerland collected from April to early May this year. Studies were done in both the severely affected urban area of Geneva, Switzerland, and the whole of Spain, capturing both strongly and less affected provinces. Both studies recruited randomly selected participants but excluded institutionalised populations (ie, permanent residents of institutions such as prisons or care homes, as well as hospitalised residents), which is a clear limitation. They relied on IgG as a marker for previous exposure, which was detected by two assays for confirmation of positive results. The Spanish study, 6 which included more than 60 000 participants, showed a nationwide seroprevalence of 5·0% (95% CI 4·7–5·4; specificity–sensitivity range of 3·7% [both tests positive] to 6·2% [at least one test positive]), with urban areas around Madrid exceeding 10% (eg, seroprevalence by immunoassay in Cuenca of 13·6% [95% CI 10·2–17·8]). These differences in seroprevalence are also reflected in laboratory-confirmed COVID-19 cases, which were much higher in urban areas than in rural areas. Similar numbers were obtained across the 2766 participants in the Swiss study, 7 with seroprevalence data from Geneva reaching 10·8% (8·2–13·9) in early May. The rather low seroprevalence in COVID-19 hotspots in both studies is in line with data from Wuhan, the epicentre and presumed origin of the SARS-CoV-2 pandemic. Surprisingly, the study done in Wuhan approximately 4–8 weeks after the peak of infection reported a low seroprevalence of 3·8% (2·6–5·4) even in highly exposed health-care workers, despite an overwhelmed health-care system. 4 None of the studies reported sex differences, and both the studies from Geneva and Spain reported lower seroprevalence in children than in adults.6, 7 Whether this reflects a lower susceptibility of children to infection in general, or rather that the studies were undertaken while schools and day-care centres were closed, remains to be elucidated. The key finding from these representative cohorts is that most of the population appears to have remained unexposed to SARS-CoV-2, even in areas with widespread virus circulation. These findings are further supported by the observation that even countries without strict lockdown measures have reported similarly low seroprevalence—eg, Sweden, which reported a prevalence of 7·3% at the end of April—leaving them far from reaching natural herd immunity in the population. 9 Such seroprevalence studies provide information only about previous exposure, rather than immunity, as no neutralising antibodies are measured. Since no correlate of protection for SARS-CoV-2 has been formally defined, we do not know what titre of neutralising antibodies would protect recovered patients from secondary infection or if non-neutralising antibodies could also contribute to protection. By analogy to common-cold coronaviruses, immunity after SARS-CoV-2 infection is thought to be incomplete and temporary, lasting only several months to a few years.10, 11 A subset of asymptomatic SARS-CoV-2 cases shows a lower antibody response and titres that wane quickly. 12 It is unknown whether these patients are protected by other immune functions, such as cellular immunity. In summary, such individuals would not be detected by serological assays but might confound the true exposure rate. In light of these findings, any proposed approach to achieve herd immunity through natural infection is not only highly unethical, but also unachievable. With a large majority of the population being infection naive, virus circulation can quickly return to early pandemic dimensions in a second wave once measures are lifted. In addition, the geographical variability and the dynamic of weekly increasing seroprevalence rates during the early phase of the pandemic highlight that these studies are only snapshots in time and space, and reflect the circumstances of the period in which they were done. As we are still in the midst of an unprecedented global health crisis, such seroprevalence data will continue to be necessary for public health authorities to estimate exposure rates, especially in areas with little testing capacity for acute cases. If and when a vaccine is widely available, ongoing seroprevalence studies will be able to provide information about the extent and duration of vaccine-induced herd immunity. © 2020 David Benito/Getty Images 2020 Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            COVID-19 zugzwang: potential public health moves towards population (herd) immunity

            Raj Bhopal (2020)
            Summary COVID-19 is pandemic, and likely to become endemic, possibly returning with greater virulence. Outlining potential public health actions, including hygiene measures, social distancing and face masks, and realistic future advances, this paper focuses on the consequences of taking no public health action; the role of natural changes such as weather; the adverse public health consequences of lockdowns; testing for surveillance and research purposes; testing to identify cases and contacts, including the role of antibody tests; the public health value of treatments; mobilising people who have recovered; population (a synonym for herd) immunity through vaccination and through natural infection; involving the entire population; and the need for public debate. Until there is a vaccine, population immunity is going to occur only from infection. Allowing infection in those at very low risk while making it safer for them and wider society needs consideration but is currently taboo. About 40-50% population immunity is sufficient to suppress an infection with a reproduction number of about 1 or slightly more. Importantly, in children and young people COVID-19 is currently rarely fatal, roughly comparable with influenza. The balance between the damage caused by COVID-19 and that caused by lockdowns needs quantifying. Public debate, including on population immunity, informed by epidemiological data, is now urgent.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Some fundamental factors concerned in the spread of infectious diseases.

              SF Dudley (1924)
                Bookmark

                Author and article information

                Journal
                Lancet
                Lancet
                Lancet (London, England)
                Elsevier Ltd.
                0140-6736
                1474-547X
                17 September 2020
                19-25 September 2020
                17 September 2020
                : 396
                : 10254
                : 810-811
                Affiliations
                [a ]Faculty of Arts and Sciences, Faculty of Medicine, and Harvard T H Chan School of Public Health, Harvard University, Cambridge, MA 02138, USA
                [b ]MIT Anthropology, Massachusetts Institute of Technology, Cambridge, MA, USA
                Article
                S0140-6736(20)31924-3
                10.1016/S0140-6736(20)31924-3
                7498207
                32950081
                4555ba1e-31b7-467e-9ef6-308e969abbb3
                © 2020 Elsevier Ltd. All rights reserved.

                Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

                History
                Categories
                Perspectives

                Medicine
                Medicine

                Comments

                Comment on this article